Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02398383 · ClinicalTrials.gov registry record · Early Phase 1
Role of Glucagon In Glucose Control in Cystic Fibrosis Related Diabetes
A Early Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 7
- Enrollment target
NCT02398383 is a Early Phase 1 study that has completed, run by Yale University. The registered enrollment target is 7 participants.
The verdict
NCT02398383, a Early Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This project is designed to begin to characterize the abnormalities of glucagon secretion in subjects with cystic fibrosis related diabetes along the spectrum of glucose tolerance. Cystic fibrosis patients with normal glucose tolerance as well as cystic fibrosis related diabetes as well as control subjects will undergo an oral glucose tolerance test, mixed meal tolerance test, and one step hypoglycemic clamp. Cystic fibrosis patients will then return 12 months later to undergo repeat mixed meal tolerance test and hypoglycemic clamp test.
Interventions
- OTHER Oral Glucose Tolerance Test
- OTHER Mixed Meal Tolerance Test
- OTHER Hypoglycemic Clamp
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2015-03 |
| Est. Completion | 2017-06-22 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02398383
The ClinicalTrials.gov registry entry for NCT02398383 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Oral Glucose Tolerance Test is the first listed.
NCT02398383 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02398383 about?
NCT02398383 is a clinical study titled "Role of Glucagon In Glucose Control in Cystic Fibrosis Related Diabetes". This project is designed to begin to characterize the abnormalities of glucagon secretion in subjects with cystic fibrosis related diabetes along the spectrum of glucose tolerance. Cystic fibrosis patients with normal glucose tolerance as well as cystic fibrosis related diabetes as well as control s...
What is the current status of trial NCT02398383?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 7 participants. The study started on 2015-03. Estimated completion is 2017-06-22.
What interventions are being tested in trial NCT02398383?
The interventions under investigation include: Oral Glucose Tolerance Test (OTHER), Mixed Meal Tolerance Test (OTHER), Hypoglycemic Clamp (OTHER).
Who is sponsoring clinical trial NCT02398383?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.